IL311212A - Suburb disease markers and their uses - Google Patents

Suburb disease markers and their uses

Info

Publication number
IL311212A
IL311212A IL311212A IL31121224A IL311212A IL 311212 A IL311212 A IL 311212A IL 311212 A IL311212 A IL 311212A IL 31121224 A IL31121224 A IL 31121224A IL 311212 A IL311212 A IL 311212A
Authority
IL
Israel
Prior art keywords
cd11b
mhcii
subject
level
farber
Prior art date
Application number
IL311212A
Other languages
English (en)
Hebrew (he)
Original Assignee
Enzyvant Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzyvant Therapeutics Gmbh filed Critical Enzyvant Therapeutics Gmbh
Publication of IL311212A publication Critical patent/IL311212A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01023—Ceramidase (3.5.1.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL311212A 2018-03-27 2019-03-22 Suburb disease markers and their uses IL311212A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862648775P 2018-03-27 2018-03-27
PCT/IB2019/000290 WO2019186272A1 (en) 2018-03-27 2019-03-22 Farber disease markers and uses thereof

Publications (1)

Publication Number Publication Date
IL311212A true IL311212A (en) 2024-05-01

Family

ID=66530353

Family Applications (2)

Application Number Title Priority Date Filing Date
IL311212A IL311212A (en) 2018-03-27 2019-03-22 Suburb disease markers and their uses
IL276420A IL276420A (en) 2018-03-27 2020-07-30 Suburb disease markers and their uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL276420A IL276420A (en) 2018-03-27 2020-07-30 Suburb disease markers and their uses

Country Status (16)

Country Link
US (2) US20190302126A1 (enExample)
EP (1) EP3775924A1 (enExample)
JP (2) JP2021516757A (enExample)
KR (2) KR20240111011A (enExample)
CN (2) CN111971562A (enExample)
AU (1) AU2019244477A1 (enExample)
BR (1) BR112020016435A2 (enExample)
CA (1) CA3090354A1 (enExample)
CL (1) CL2020002105A1 (enExample)
CO (1) CO2020010043A2 (enExample)
IL (2) IL311212A (enExample)
MX (1) MX2020008377A (enExample)
PH (1) PH12020551206A1 (enExample)
RU (1) RU2020119065A (enExample)
SG (1) SG11202007508TA (enExample)
WO (1) WO2019186272A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220088158A1 (en) * 2019-01-23 2022-03-24 Aceragen, Inc. Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase
CA3209730A1 (en) * 2021-03-29 2022-10-06 Alan Parker Modified adenovirus
CN117647649A (zh) * 2023-08-15 2024-03-05 迈健医药科技无锡有限公司 一种免疫细胞全维分析的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
CA2163860A1 (en) 1993-06-30 1995-01-12 Chung C. Hsu Method for preparing liposomes
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
JP6832158B2 (ja) 2013-03-14 2021-02-24 アイカーン スクール オブ メディシン アット マウント サイナイ 治療用酸性セラミダーゼ組成物ならびにそれを作製および使用する方法
EP3115786A1 (en) * 2015-07-08 2017-01-11 Centogene AG Method for the diagnosis of farber's disease

Also Published As

Publication number Publication date
BR112020016435A2 (pt) 2020-12-15
KR20200136367A (ko) 2020-12-07
MX2020008377A (es) 2020-09-25
CO2020010043A2 (es) 2020-11-10
RU2020119065A (ru) 2022-04-27
PH12020551206A1 (en) 2021-04-19
EP3775924A1 (en) 2021-02-17
CN111971562A (zh) 2020-11-20
SG11202007508TA (en) 2020-09-29
CL2020002105A1 (es) 2020-12-04
CN118112249A (zh) 2024-05-31
JP2021516757A (ja) 2021-07-08
US20190302126A1 (en) 2019-10-03
WO2019186272A1 (en) 2019-10-03
US20210199670A1 (en) 2021-07-01
AU2019244477A1 (en) 2020-06-25
CA3090354A1 (en) 2019-10-03
JP2023159164A (ja) 2023-10-31
KR20240111011A (ko) 2024-07-16
IL276420A (en) 2020-09-30

Similar Documents

Publication Publication Date Title
JP2025148351A (ja) 疾病の薬理シャペロン治療に対する応答性を予測する方法
US7105330B2 (en) Human plasma hyaluronidase
JP2023159164A (ja) ファーバー病マーカーおよびその使用
US20250170225A1 (en) Compositions and methods for treating farber disease
US20230123505A1 (en) Methods for treating farber disease
CN1750834A (zh) 用于治疗蛋白质缺乏病的联合治疗
CN1737133A (zh) 高纯度蛇毒纤溶酶的制备方法及其药物制剂
US20250205315A1 (en) Recombinant tmem2 extracellular domain and uses thereof
US20040266677A1 (en) Method of diagnosing and treating lens illnesses using human HSF4 gene and coded product thereof
WO2025029880A1 (en) Neuroprotection and axon regeneration therapies for cns axonopathies by modulating mitochondria trafficking through optn, trak1, and kif5b
HK40105998A (en) Compositions and methods for treating farber disease
US20220332812A1 (en) Treatment methods for eye disorders
JP2018538008A (ja) リソソーム酵素の取り込みを中和する抗体または他の因子の検出のための細胞ベースアッセイ
CN121718626A (zh) 用于心力衰竭的诊断和治疗的标志物及其应用
Lieber A Combination Therapy of JO-I and Chemotherapy in Ovarian Cancer Models